Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients

Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2000, Pages 335-342

  Moreno, Fuensanta ^a   Sanz Guajardo, Dámaso ^b   López Gómez, Juan Manuel ^c   Jofre, Rosa ^c   Valderrábano, Fernando ^c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0033968567     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 300: 573-578, 1990
2. Laupacis A, Wong C, Churchill D: The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials 12[Suppl 4]: 168S-179S, 1991
3. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263: 825-830, 1990
4. Moreno F, Aracil FJ, Perez R, Valderrábano F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27: 548-556, 1996
5. Moreno F, López-Gómez F, Sanz Guajardo D, Jofre R, Valderrábano F: Quality of life in dialysis patients: A Spanish multicenter study. Nephrol Dial Transplant 11[Suppl 2]: 125-129, 1996
6. McMahon LP, Dawborn JK: Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 12: 162-169, 1992
7. Valderrábano F: Erythropoietin in chronic renal failure. Kidney Int 50: 1373-1391, 1996
8. National Kidney Foundation-Dialysis Outcomes Quality Initiative: Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30[Suppl 3]: S192-S240, 1997
9. Besarab A, Bolton K, Browne J, Egrie J, Nissenson A, Okamoto D, Schwab S, Goodkin D: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339: 584-590, 1998
10. Lim V: Recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 18[Suppl 1]: 34-37, 1991
11. Suzuki M, Tsutsui M, Yokoyama A, Hirasawa Y: Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise abilities. Artif Organs 19: 1258-1261, 1995
12. Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Easterling T, Donney J, Schneider G: Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe [Abstract]. J Am Soc Nephrol 4: 425, 1993
13. Sangkabutra T, McKenna MJ, Mason K, Crankshaw DP, McMahon LP: Effects of K, pH and different haemoglobin levels on maximal exercise performance in haemodialysis patients. Nephrology 3(Suppl 1): S304, 1997
14. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR: RHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155-163, 1991
15. Nissenson AR, Pickett JL, Theberge DC, Brown WS, Schweitzer SV: Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin. J Am Soc Nephrol 7: 1459, 1996
16. Benz RL, Pressman MR, Hovick ET, Peterson DD: Relationship between anemia of chronic renal failure and sleep, sleep disorders and daytime alertness: Benefits of normalizing hematocrit (The Sleepo Trial). J Am Soc Nephrol 7: 1473, 1996
17. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents, edited by Macleod CM, New York, New York Columbia University Press, 1949, pp 191-205
18. Conill C, Verger E, Salamero M: Performance status assessment in cancer patients. Cancer 65: 1864-1866, 1990
19. Mercier M, Schraub S, Bransfield B, Fournier J: Patient acceptance and differential perceptions of quality of life measures in a French oncology setting. Qual Life Res 1: 53-61, 1992
20. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The sickness impact profile: Development and final revision of a health-status measure. Med Care 19: 787-805, 1981
21. Hendricson WD, Russell IJ, Prihoda TJ, Jacobson JM, Rogan A, Bishop GD: An approach to developing a valid Spanish language translation of a health-status questionnaire. Med Care 27: 959-966, 1989
22. Friedman E: Diabetic nephropathy. In: Therapy of Renal Diseases and Related Disorders, 2nd Ed., edited by Suky WN, Massry SG, Boston, Kluwer Academic Publishers, 1991, pp 534-542
23. Daugirdas JT: Chronic hemodialysis prescription: A urea kinetic approach. In: Handbook of Dialysis, 2nd Ed., edited by Daugirdas JT, Ing TS, Boston, Little Brown & Co., 1994, pp 92-120
24. Wilcoxon F: Individual comparisons by ranking methods. Biometrika Bull 1: 80-83, 1945
25. Prentice RL: Exponential survivals with censoring and explanatory variables. Biometrika 60: 279-288, 1973
26. Kusunoki M, Kimura K, Nakamura M, Isaka Y, Yoneda S, Abe H: Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease. J Cereb Blood Flow Metab 1: 413-417, 1981
27. Adamson JW, Eschbach JW: Erythropoietin for end-stage renal disease. N Engl J Med 339: 625-627, 1998
28. Macdougall I, Ritz E: The Normal Haematocrit Trial in dialysis patients with cardiac disease: Are we any the less confused about target haemoglobin. Nephrol Dial Transplant 13: 3030-3033, 1998
29. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
30. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316, 1999
31. Ma J, Ebben J, Xia H, Collins J: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
32. Locatelli F, Conte F, Marcelli D: The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13: 1642-1644, 1998
33. Churchill DN, for the Canadian Hemodialysis Morbidity Study Group: Morbidity in chronic hemodialysis patients: A study of prognosis. Kidney Int 37: 291, 1990
34. Muirhead N, Laupacis A, Wong C: Erythropoietin for anaemia in haemodialysis patients: Results of a maintenance study. The Canadian Erythropoietin Study Group. Nephrol Dial Transplant 7: 811-816, 1992
35. Paganini EP, Latham D, Abdulhadi M: Practical considerations of recombinant erythropoietin therapy. Am J Kidney Dis 14: 19-28, 1989
36. Eschbach JW, Aquilling T, Haley NR, Fan MH, Blagg CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38[Suppl 1]: S23-S28, 1992
37. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578-583, 1998